Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Journal of Chromatography
|
October 29, 1993
Determination of the new podophyllotoxin derivative NK 611 in plasma by high-performance liquid chromatography with ultraviolet detection
A Hüttmann, K Mross, D K Hossfeld
Annals of Hematology
|
August 5, 2003
Bone marrow-derived stem cells and "plasticity"
A Hüttmann, C L Li, U Dührsen
Journal of Cancer Research and Clinical Oncology
|
December 8, 2004
Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
A Hüttmann, K Schirsafi, S Seeber, et al.
Experimental Hematology
|
September 5, 2001
Functional heterogeneity within rhodamine123(lo) Hoechst33342(lo/sp) primitive hemopoietic stem cells revealed by pyronin Y
A Hüttmann, S L Liu, A W Boyd, et al.
Blood
|
September 25, 1999
Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells
M Dottori, M Down, A Hüttmann, et al.
Leukemia
|
February 13, 2002
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia
J Dürig, M Naschar, U Schmücker, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH
K Mross, A Hüttmann, K Herbst, et al.
Investigational New Drugs
|
July 30, 1999
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
I Rassmann, R Thödtmann, M Mross, et al.
Leukemia
|
August 26, 2006
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status
A Hüttmann, L Klein-Hitpass, J Thomale, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 26, 2021
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma
Mje Greuter, J J Eertink, G Jongeneel, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Journal of Chromatography
|
October 29, 1993
Determination of the new podophyllotoxin derivative NK 611 in plasma by high-performance liquid chromatography with ultraviolet detection
A Hüttmann, K Mross, D K Hossfeld
Annals of Hematology
|
August 5, 2003
Bone marrow-derived stem cells and "plasticity"
A Hüttmann, C L Li, U Dührsen
Journal of Cancer Research and Clinical Oncology
|
December 8, 2004
Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
A Hüttmann, K Schirsafi, S Seeber, et al.
Experimental Hematology
|
September 5, 2001
Functional heterogeneity within rhodamine123(lo) Hoechst33342(lo/sp) primitive hemopoietic stem cells revealed by pyronin Y
A Hüttmann, S L Liu, A W Boyd, et al.
Blood
|
September 25, 1999
Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells
M Dottori, M Down, A Hüttmann, et al.
Leukemia
|
February 13, 2002
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia
J Dürig, M Naschar, U Schmücker, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH
K Mross, A Hüttmann, K Herbst, et al.
Investigational New Drugs
|
July 30, 1999
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
I Rassmann, R Thödtmann, M Mross, et al.
Leukemia
|
August 26, 2006
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status
A Hüttmann, L Klein-Hitpass, J Thomale, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 26, 2021
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma
Mje Greuter, J J Eertink, G Jongeneel, et al.
Page
of 2